Detail akcie Genscript Biotech online

Business Summary: Genscript Biotech Corp is an investment holding company principally engaged in the manufacture and sale of life science research products and services. The Company operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The Company mainly operates its businesses in the domestic and overseas markets.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Genscript Biotech Corp revenues increased 82% to $518.8M. Net loss before extraordinary items decreased 74% to $25.5M. Revenues reflect Biologics development services segment increase from $37.1M to $244M, Life science services and products segment increase of 13% to $245.1M. Lower net loss reflects Fair Value Adjustments on Other Assets decrease of 88% to $13.8M (expense).